As a core link in the pharmaceutical industry chain, pharmaceutical intermediates are now empowered by three major forces: policy, technology and market. Amid the global shift of the pharmaceutical industry toward higher added value, coupled with the domestic boom in innovative drug R&D and rising demand for supply chain security, the sector is undergoing a comprehensive transformation from traditional chemical manufacturing to greener, smarter and higher-end production. The next five years will mark a golden period of structural growth for the industry.
Continuous expansion of market size serves as the core driver of industrial development. Data shows that the domestic market scale of pharmaceutical intermediates reached 65 billion yuan in 2023 and is projected to exceed 150 billion yuan by 2030, with a compound annual growth rate of around 14%. Growth is mainly driven by two areas: first, accelerated R&D of innovative drugs, where demand for high-end intermediates such as anti-tumor and GLP‑1 class products is growing at more than 21% annually and will account for 58% of the market by 2030; second, expanded room for import substitution, where the self-sufficiency rate of high-end chiral intermediates and biocatalytic intermediates currently stands at less than 40%, and is expected to rise to over 70% by 2028.
Policies and environmental requirements are jointly reshaping the industry landscape. The 14th Five-Year Plan explicitly mandates a 13.5% reduction in energy consumption per unit of GDP. New environmental regulations have already led to the shutdown of 137 non-compliant enterprises, significantly raising industry entry barriers. Meanwhile, the Implementation Plan for Digital-Intelligent Transformation of the Pharmaceutical Industry and local industrial subsidy policies have created synergies. For instance, Luzhou offers a 1-million-yuan reward for API registration, encouraging enterprises to pursue compliance and high-end development. Guided by policies, industrial clusters in the Yangtze River Delta, Chengdu-Chongqing region and other areas have shown strong agglomeration effects, and leading enterprises will further increase their market share.
Technological innovation has become the core competitiveness. Green production has become an industry standard. Technologies such as biocatalysis and continuous-flow reactions have increased product yields by 10–20 percentage points and reduced energy consumption by 22%. Intelligent transformation is accelerating: the application rate of automated production lines and industrial internet has reached 65%, and technologies such as digital twins are reshaping production and management models. In high-end sectors, domestic enterprises have achieved breakthroughs in key technologies including chiral synthesis and enzyme catalysis, gradually breaking the monopoly of Europe and the United States.
Global layout has opened up new growth space. Supported by the Belt and Road Initiative, domestic enterprises are strengthening cooperation with Southeast Asia, Central Asia and other regions, with exports expected to exceed 12 billion US dollars by 2030. At the same time, leading enterprises are integrating into the global high-end supply chain by establishing overseas factories and obtaining FDA DMF filings, and transitioning from product suppliers to integrated service providers under the CDMO model.
With both challenges and opportunities coexisting, the pharmaceutical intermediates industry will feature a “strong get stronger” pattern in the future. Enterprises must focus on green technology R&D, intelligent upgrading and breakthroughs in high-end products to seize opportunities amid the dual dividends of policy-driven industry consolidation and market upgrading, and promote high-quality and sustainable development of the industry.
